{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T10:10:47Z","timestamp":1768817447074,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T00:00:00Z","timestamp":1490918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.cmi.2017.03.023","type":"journal-article","created":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T05:49:01Z","timestamp":1491025741000},"page":"882-887","source":"Crossref","is-referenced-by-count":45,"title":["Evaluation of the in\u00a0vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates"],"prefix":"10.1016","volume":"23","author":[{"given":"K.M.T.","family":"Astvad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.K.","family":"Hare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.C.","family":"Arendrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2017.03.023_bib1","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1128\/JCM.00863-13","article-title":"In\u00a0vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds","volume":"51","author":"Pfaller","year":"2013","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2017.03.023_bib2","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1128\/AAC.01111-13","article-title":"Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method","volume":"57","author":"Howard","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2017.03.023_bib3","doi-asserted-by":"crossref","first-page":"7735","DOI":"10.1128\/AAC.01919-15","article-title":"In\u00a0vitro activity of isavuconazole and comparators against clinical isolates of the Mucorales order","volume":"59","author":"Arendrup","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2017.03.023_bib4","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1128\/AAC.00685-10","article-title":"In\u00a0vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens","volume":"54","author":"Guinea","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2017.03.023_bib5","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1128\/AAC.01217-06","article-title":"In\u00a0vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates","volume":"51","author":"Seifert","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2017.03.023_bib6","series-title":"Cresemba: EPAR \u2013 Product information","author":"European Medicines Agency (EMA)","year":"2015"},{"key":"10.1016\/j.cmi.2017.03.023_bib7","series-title":"Cresemba (isavuconazonium sulfate) prescribing information","author":"U.S. Food and Drug Administration. Astellas Pharma US","year":"2015"},{"key":"10.1016\/j.cmi.2017.03.023_bib8","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2017.03.023_bib9","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2017.03.023_bib10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drup.2015.08.001","article-title":"International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus","volume":"21\u201322","author":"Verweij","year":"2015","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.cmi.2017.03.023_bib11","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2017.03.023_bib12","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1128\/AAC.04586-14","article-title":"A\u00a0phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis","volume":"59","author":"Viljoen","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2017.03.023_bib13","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1111\/1469-0691.12212","article-title":"Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme","volume":"19","author":"Arendrup","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2017.03.023_bib14","doi-asserted-by":"crossref","first-page":"5096","DOI":"10.1128\/AAC.02855-14","article-title":"First detection of TR46\/Y121F\/T289A and TR34\/L98H alterations in Aspergillus fumigatus isolates from azole-naive patients in Denmark despite negative findings in the environment","volume":"58","author":"Astvad","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2017.03.023_bib15","doi-asserted-by":"crossref","first-page":"571.e1","DOI":"10.1016\/j.cmi.2016.01.017","article-title":"EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents","volume":"22","author":"Arendrup","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2017.03.023_bib16","doi-asserted-by":"crossref","first-page":"E278","DOI":"10.1111\/1469-0691.12148","article-title":"EUCAST Technical Note on voriconazole and Aspergillus spp.","volume":"19","author":"Hope","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2017.03.023_bib17","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Isavuconazole and Aspergillus spp.: rationale for the clinical breakpoints, version 1.0. Available at: http:\/\/www.eucast.org."},{"key":"10.1016\/j.cmi.2017.03.023_bib18","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1469-0691.2008.02087.x","article-title":"EUCAST technical note on voriconazole","volume":"14","author":"Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST)*","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2017.03.023_bib19","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1128\/AAC.01256-09","article-title":"Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media","volume":"54","author":"Arendrup","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2017.03.023_bib20","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1128\/AAC.00692-10","article-title":"Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain","volume":"54","author":"Mortensen","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2017.03.023_bib21","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/infdis\/jis442","article-title":"In\u00a0vivo emergence of Aspergillus terreus with reduced azole susceptibility and a Cyp51a M217I alteration","volume":"206","author":"Arendrup","year":"2012","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2017.03.023_bib22","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1128\/AAC.48.11.4405-4413.2004","article-title":"In\u00a0vitro evolution of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of resistance","volume":"48","author":"da Silva Ferreira","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2017.03.023_bib23","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1128\/AAC.00636-13","article-title":"Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method","volume":"57","author":"Espinel-Ingroff","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2017.03.023_bib24","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1128\/AAC.01512-07","article-title":"In\u00a0vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species","volume":"52","author":"Guinea","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2017.03.023_bib25","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3201\/eid2106.140717","article-title":"Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus","volume":"21","author":"van der Linden","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.cmi.2017.03.023_bib26","doi-asserted-by":"crossref","first-page":"570.e1","DOI":"10.1016\/j.cmi.2016.04.001","article-title":"Azole-resistant Aspergillus fumigatus in Denmark: a laboratory-based study on resistance mechanisms and genotypes","volume":"22","author":"Jensen","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2017.03.023_bib27","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1469-0691.2006.01377.x","article-title":"Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values","volume":"12","author":"Turnidge","year":"2006","journal-title":"Clin Microbiol Infect"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X17301921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X17301921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T06:04:33Z","timestamp":1657433073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X17301921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S1198743X17301921"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2017.03.023","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]}}}